Patents
Intellectual Property
Our Patent Portfolio
| Country | Application # | ALPHA-1062 Technologies | Anticipated Expiration Date |
| CA / CN / JP | 2,721,007 / ZL200880128608.5 / 5504253 | DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES | 2028+ |
| US | US 9,763,953 / 10,265,325 | CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT | 2026+ |
| EP | 2 137 192 | DERIVATIVES OF GALANTAMINE AS PRO-DRUGS FOR THE TREATMENT OF HUMAN BRAIN DISEASES | 2028+ |
| EP / CA / AU / JP/ JP / JP | 2877165 / 2878135 2013294917 / 6272857 / 6574002 / 2019-148915 | ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS | 2033 |
| CN / HK / IN / US | 2018101403258 / 19100111.3 / 201918046982/ 16/287,413 | ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS | 2033 |
| EP | Pending | SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 | 2040 |
| EP | 21152317.0 | Gluconate Polymorphs / API Manufacturing / Enteric Coated Tablet Synthesis / Sub-lingual Tablet Synthesis | 2041 |
| Country | Application # | ALPHA-0600 Series | Anticipated Expiration Date |
| CA / CN / IN | Pending / CN102006882 / 280570 | PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE | 2029 |
| US | Pending | TREATING NEURODEGENRATIVE DISEASE WITH PROGRANULIN | 2028+ |
| EP / EP | 2 249 861 / 3 009 143 | PROGRANULIN FOR USE IN TREATING PARKINSON’S DISEASE OR ALZHEIMER’S DISEASE | 2029+ |
| US / JP | Pending / 6312436 | METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY | 2031 |
+ Potential Patent Term Adjustment (35 U.S.C. §154) and Patent Term Extension (35 U.S.C. §156) compensate patent applicants for USPTO / FDA -caused delays, adding up to as much as 5 years of patent life.
